1. Home
  2. LOOP vs CGTX Comparison

LOOP vs CGTX Comparison

Compare LOOP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loop Industries Inc.

LOOP

Loop Industries Inc.

HOLD

Current Price

$0.49

Market Cap

39.7M

Sector

Industrials

ML Signal

HOLD

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.03

Market Cap

79.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOOP
CGTX
Founded
2010
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
79.6M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
LOOP
CGTX
Price
$0.49
$1.03
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
1.4M
519.4K
Earning Date
05-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
27.27
62.79
EPS
N/A
N/A
Revenue
$10,889,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$174.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7016.99
N/A
52 Week Low
$0.46
$0.55
52 Week High
$1.99
$2.67

Technical Indicators

Market Signals
Indicator
LOOP
CGTX
Relative Strength Index (RSI) 26.38 52.55
Support Level N/A $1.02
Resistance Level $0.97 $1.18
Average True Range (ATR) 0.07 0.05
MACD -0.01 0.01
Stochastic Oscillator 5.97 73.32

Price Performance

Historical Comparison
LOOP
CGTX

About LOOP Loop Industries Inc.

Loop Industries Inc is a technology company whose mission is to accelerate the world's shift toward sustainable PET plastic and polyester fiber and away from dependence on fossil fuels. Loop Industries owns patented and proprietary technology that depolymerizes no and low-value waste PET plastic and polyester fiber, including plastic bottles, packaging, and textiles such as carpets and clothing, into its base building block monomers, DMT and MEG.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: